In the American Porphyria Foundation's announcement about the posting of the videos, they end by saying:
"In an upcoming eNnews, you can read how three APF members, Matt Johnson, Steve Ferry and Mike Kenworthy, were a major force in the approval of the Phase III trials with Afamelanotide. We owe them our thanks."
The APF has really been an extraordinarily positive force in helping to push this through the regulatory process with the FDA.
epp patient fda video, page-2
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |